Form 4: Cellectar Biosciences Consultant Receives Stock Option

Cellectar Biosciences, Inc. consultant Loren Stefan was granted a stock option for 15,000 shares.

Summary

• Loren Stefan, a consultant for Cellectar Biosciences, Inc., was granted a stock option on July 8, 2026.
• The stock option is for 15,000 shares of common stock.
• The exercise price for the option is $2.68 per share.
• The option is set to vest in full on July 8, 2027, contingent upon Stefan's continued service to the company.
• The option has an expiration date of July 8, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard equity award to a consultant rather than a significant financial event for the company.

Positives

• Granting of stock options can incentivize key personnel and align their interests with shareholders.
• The option provides a potential future benefit to the consultant, tied to the company's stock performance.

Negatives

• The value of the stock option is contingent on the future performance of Cellectar Biosciences' stock price exceeding the exercise price of $2.68.

Risks

• The value of the stock option is subject to market volatility and the company's future financial performance.
• The vesting is contingent on continued service, meaning the option could be forfeited if employment is terminated before July 8, 2027.

Future Outlook

The future outlook for the stock option is dependent on the company's stock performance and the consultant's continued employment. The option provides a potential upside if the stock price rises above $2.68 before its expiration in 2036.

Industry Context

StockSavvy.ai notes that the granting of stock options to consultants is a common practice in the biotechnology sector to attract and retain specialized talent, especially for companies focused on research and development where long-term incentives are crucial.

Stakeholder Impact

• Shareholders: The issuance of stock options can lead to dilution if exercised, but also aligns consultant incentives with stock appreciation.
• Consultant (Loren Stefan): Receives a potential financial benefit tied to the company's performance.

Next Steps

• Loren Stefan to continue service through July 8, 2027, to ensure full vesting of the stock option.
• Monitor Cellectar Biosciences' stock performance relative to the $2.68 exercise price.

Key Dates

Keywords

Cellectar Biosciences, CLRB, Form 4, Stock Option, Consultant, SEC Filing, Beneficial Ownership, Equity Award